“Multiple Myeloma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple Myeloma Market.
The Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Multiple Myeloma Pipeline Report:
Companies across the globe are diligently working toward developing novel Multiple Myeloma treatment therapies with a considerable amount of success over the years.
Multiple Myeloma companies working in the treatment market are Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, and others, are developing therapies for the Multiple Myeloma treatment
Emerging Multiple Myeloma therapies in the different phases of clinical trials are- Zevorcabtagene Autoleucel, Descartes 08, GC012F, P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, and others are expected to have a significant impact on the Multiple Myeloma market in the coming years.
In February 2023, Elranatamab’s marketing authorization application (MAA) was approved, according to the European Medicines Agency (EMA). The US Food and Drug Administration (FDA) has approved the company’s Biologics License Application (BLA) for elranatamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM), according to a separate announcement from Pfizer.
Multiple Myeloma Overview
Monoclonal immunoglobulin levels abnormally rise in multiple myeloma (MM), a clonal plasma cell proliferation condition. Uncontrolled synthesis of these plasma cells can eventually result in specific end-organ damage.
Get a Free Sample PDF Report to know more about Multiple Myeloma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight
Emerging Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:
Zevorcabtagene Autoleucel: Carsgen Therapeutics
Descartes 08: Cartesian Therapeutics
GC012F: Gracell Biotechnology Shanghai Co., Ltd.
P-BCMACD19- ALLO1: Poseida Therapeutics
ION251: Ionis Pharmaceuticals
CID-103: CASI Pharmaceuticals
STI-1492: Sorrento Therapeutics
RAPA-201: Rapa Therapeutics
PHE885: Novartis
Venetoclax: AbbVie
Elranatamab: Pfizer
Multiple Myeloma Route of Administration
Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Multiple Myeloma Molecule Type
Multiple Myeloma Products have been categorized under various Molecule types, such as
Small molecule
Cell Therapy
Peptides
Polymer
Gene therapy
Multiple Myeloma Pipeline Therapeutics Assessment
Multiple Myeloma Assessment by Product Type
Multiple Myeloma By Stage and Product Type
Multiple Myeloma Assessment by Route of Administration
Multiple Myeloma By Stage and Route of Administration
Multiple Myeloma Assessment by Molecule Type
Multiple Myeloma by Stage and Molecule Type
DelveInsight’s Multiple Myeloma Report covers around 80+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Multiple Myeloma product details are provided in the report. Download the Multiple Myeloma pipeline report to learn more about the emerging Multiple Myeloma therapies
Some of the key companies in the Multiple Myeloma Therapeutics Market include:
Key companies developing therapies for Multiple Myeloma are – Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Sanofi S.A., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., Ltd., Novartis International, AGTeva Pharmaceutical Industries Ltd., Johnson and Johson, Inc. (Janssen Pharmaceuticals), AbbVie Inc., GlaxoSmithKline plc, Harpoon Therapeutics, and others.
Multiple Myeloma Pipeline Analysis:
The Multiple Myeloma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Myeloma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma Treatment.
Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Myeloma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Multiple Myeloma drugs and therapies
Multiple Myeloma Pipeline Market Drivers
Rising prevalence of multiple myeloma worldwide, increasing investment for healthcare infrastructure are some of the important factors that are fueling the Multiple Myeloma Market.
Multiple Myeloma Pipeline Market Barriers
However, high cost associated with the treatment of multiple myeloma, lack of healthcare infrastructure in developing economies and other factors are creating obstacles in the Multiple Myeloma Market growth.
Scope of Multiple Myeloma Pipeline Drug Insight
Coverage: Global
Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, and others
Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, and others
Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers
Request for Sample PDF Report for Multiple Myeloma Pipeline Assessment and clinical trial
Table of Contents
1. Multiple Myeloma Report Introduction
2. Multiple Myeloma Executive Summary
3. Multiple Myeloma Overview
4. Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment
5. Multiple Myeloma Pipeline Therapeutics
6. Multiple Myeloma Late Stage Products (Phase II/III)
7. Multiple Myeloma Mid Stage Products (Phase II)
8. Multiple Myeloma Early Stage Products (Phase I)
9. Multiple Myeloma Preclinical Stage Products
10. Multiple Myeloma Therapeutics Assessment
11. Multiple Myeloma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Multiple Myeloma Key Companies
14. Multiple Myeloma Key Products
15. Multiple Myeloma Unmet Needs
16 . Multiple Myeloma Market Drivers and Barriers
17. Multiple Myeloma Future Perspectives and Conclusion
18. Multiple Myeloma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las vegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
